LIQUIDIA CORP (LQDA) Stock Price & Overview
NASDAQ:LQDA • US53635D2027
Current stock price
The current stock price of LQDA is 35.7 USD. Today LQDA is down by -2.62%. In the past month the price decreased by -6.54%. In the past year, price increased by 136.11%.
LQDA Key Statistics
- Market Cap
- 3.106B
- P/E
- N/A
- Fwd P/E
- 18.95
- EPS (TTM)
- -0.81
- Dividend Yield
- N/A
LQDA Stock Performance
LQDA Stock Chart
LQDA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to LQDA. When comparing the yearly performance of all stocks, LQDA is one of the better performing stocks in the market, outperforming 94.99% of all stocks.
LQDA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to LQDA. LQDA may be in some trouble as it scores bad on both profitability and health.
LQDA Earnings
On March 5, 2026 LQDA reported an EPS of 0.17 and a revenue of 92.02M. The company missed EPS expectations (-7.63% surprise) and beat revenue expectations (7.87% surprise).
LQDA Forecast & Estimates
15 analysts have analysed LQDA and the average price target is 46.58 USD. This implies a price increase of 30.48% is expected in the next year compared to the current price of 35.7.
For the next year, analysts expect an EPS growth of 332.55% and a revenue growth 219.14% for LQDA
LQDA Groups
Sector & Classification
LQDA Financial Highlights
Over the last trailing twelve months LQDA reported a non-GAAP Earnings per Share(EPS) of -0.81. The EPS increased by 51.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -21.02% | ||
| ROE | -154.03% | ||
| Debt/Equity | 2.97 |
LQDA Ownership
LQDA Latest News, Press Relases and Analysis
LQDA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.3 | 929.285B | ||
| JNJ | JOHNSON & JOHNSON | 20.88 | 582.039B | ||
| MRK | MERCK & CO. INC. | 22.3 | 285.833B | ||
| PFE | PFIZER INC | 8.91 | 151.141B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.43 | 120.315B | ||
| ZTS | ZOETIS INC | 16.69 | 48.807B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.92 | 26.334B | ||
| VTRS | VIATRIS INC | 5.39 | 15.555B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.24 | 11.405B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.983B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.157B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.94B | ||
| LGND | LIGAND PHARMACEUTICALS | 24.47 | 4.046B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LQDA
Company Profile
Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company is headquartered in Morrisville, North Carolina and currently employs 157 full-time employees. The company went IPO on 2018-07-26. The firm is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The firm operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Company Info
IPO: 2018-07-26
LIQUIDIA CORP
419 Davis Drive, Suite 100
Morrisville NORTH CAROLINA 27560 US
CEO: Neal Fowler
Employees: 170
Phone: 19193284400
LIQUIDIA CORP / LQDA FAQ
What does LIQUIDIA CORP do?
Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company is headquartered in Morrisville, North Carolina and currently employs 157 full-time employees. The company went IPO on 2018-07-26. The firm is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The firm operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
What is the stock price of LIQUIDIA CORP today?
The current stock price of LQDA is 35.7 USD. The price decreased by -2.62% in the last trading session.
Does LQDA stock pay dividends?
LQDA does not pay a dividend.
What is the ChartMill rating of LIQUIDIA CORP stock?
LQDA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is LQDA stock listed?
LQDA stock is listed on the Nasdaq exchange.
What is the market capitalization of LQDA stock?
LIQUIDIA CORP (LQDA) has a market capitalization of 3.11B USD. This makes LQDA a Mid Cap stock.
What is the next earnings date for LQDA stock?
LIQUIDIA CORP (LQDA) will report earnings on 2026-05-06, before the market open.